NASDAQ:HRTS Tema Heart & Health ETF (HRTS) Price, Holdings, & News $29.26 0.00 (0.00%) As of 12:38 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestTrendsBuy This Stock About Tema Heart & Health ETF (NASDAQ:HRTS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get HRTS alerts:Sign Up Key Stats Today's Range$29.26▼$29.3750-Day Range$27.45▼$29.2852-Week Range$25.32▼$35.59Volume1,621 shsAverage Volume8,751 shsMarket Capitalization$49.16 millionAssets Under Management$48.28 millionDividend Yield1.57%Net Expense Ratio0.75%Aggregate RatingModerate Buy ETF Overview The Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive. HRTS was launched on Nov 20, 2023 and is issued by Tema. Read More Tema Heart & Health ETF ExpensesTypeHRTSTheme ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.99%0.57%0.56%0.54%0.53%Other Expenses0.00%0.57%0.56%0.52%0.56%Total Expense0.99%0.74%0.76%0.73%0.73%Fee Waiver-0.24%-0.76%-0.66%-0.50%-0.63%Net Expense0.75%0.60%0.63%0.63%0.60% Receive HRTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tema Heart & Health ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address HRTS ETF News HeadlinesTEMA HEART & HEALTH ETF ETFs | Markets InsiderAugust 7, 2025 | markets.businessinsider.comWeight-Loss Drug ETFs Generate Skinnier Returns Than ExpectedJune 11, 2025 | finance.yahoo.comFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained to stay alive when systems collapse. In Operation Gold Rush, Jason Hanson reveals how gold and silver saved his life—and how they could protect yours in the next crisis. You’ll learn how to hide gold like a covert operative, secure your 401(k) in physical assets, and prepare for grid failures, economic collapse, or worse.August 18 at 2:00 AM | Advantage Gold (Ad)HRTS Tema Obesity & Cardiometabolic ETFApril 10, 2025 | seekingalpha.comHRT may help to protect the heartOctober 22, 2024 | dailymail.co.ukInvesting in Real Assets: The Growing Demand and Opportunity with Brompton’s BREA ETFOctober 10, 2024 | theglobeandmail.comSee More Headlines HRTS ETF - Frequently Asked Questions How have HRTS shares performed this year? Tema Heart & Health ETF's stock was trading at $28.87 at the beginning of 2025. Since then, HRTS shares have increased by 1.4% and is now trading at $29.26. Who are Tema Heart & Health ETF's major shareholders? Tema Heart & Health ETF's top institutional shareholders include Sterling Investment Advisors Ltd. (10.02%), Jane Street Group LLC (2.21%), Oliver Lagore Vanvalin Investment Group (1.73%) and Flow Traders U.S. LLC (1.09%). How do I buy shares of Tema Heart & Health ETF? Shares of HRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tema Heart & Health ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tema Heart & Health ETF investors own include Scilex (SCLX), Rigetti Computing (RGTI), Pfizer (PFE), BlackBerry (BB), Butterfly Network (BFLY), BioNTech (BNTX) and Fund Details IssuerTema Global Fund NameTema Heart & Health ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:HRTS Inception Date11/20/2023 Fund ManagerDavid Song, Yuri Khodjamirian Previous SymbolNASDAQ:HRTS WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkN/A CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings91 Fund Statistics Assets Under Management$48.28 million Average Daily Volume$0.00 Discount/Premium-0.03% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorTema Global Limited CustodianU.S. Bank, N.A. DistributorForeside Fund Services, LLC Transfer AgentU.S. Bancorp Fund Services, LLC TrusteeN/A Lead Market MakerVirtu Financial Options OptionableOptionable Options Volume1 Put Options3 Call Options1 Short Interest200 shs Miscellaneous Outstanding Shares1,680,000Beta0.93 Creation Unit10,000 Creation Fee$500.00 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report Top 10 HRTS HoldingsEli Lilly and Company (NYSE:LLY)Holding Weight: 10.06%Abbott Laboratories (NYSE:ABT)Holding Weight: 4.75%AstraZeneca PLCHolding Weight: 4.36%Roche (OTCMKTS:RHHBY)Holding Weight: 4.03%Gilead Sciences (NASDAQ:GILD)Holding Weight: 3.55%UnitedHealth Group (NYSE:UNH)Holding Weight: 3.51%BridgeBio Pharma (NASDAQ:BBIO)Holding Weight: 3.50%Medtronic (NYSE:MDT)Holding Weight: 3.48%AbbVie (NYSE:ABBV)Holding Weight: 3.47%Boston Scientific (NYSE:BSX)Holding Weight: 3.34%Full Holdings DetailsHRTS Sector ExposureHRTS Industry Exposure This page (NASDAQ:HRTS) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | Sponsored"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Heart & Health ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Heart & Health ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access